Description

This fixed-dose combination features 100?mg lopinavir (an HIV-1 protease inhibitor) and 25?mg ritonavir (a CYP3A inhibitor that enhances lopinavir exposure). Historically offered as part of antiretroviral therapy under the brand name Aluvia, it is widely studied in research to model viral suppression, drug–drug interactions, pharmacokinetics, and resistance pathways. Each tablet profile supports consistent, reproducible dosing in laboratory protocols involving HIV?1 replication or antiviral screening.

Product Specifications

Mechanism of Action & Research Applications

Lopinavir directly inhibits HIV-1 protease enzyme, preventing viral polyprotein processing. Ritonavir slows the metabolism of lopinavir via CYP3A inhibition, boosting and prolonging its systemic levels. This combination is ideal for research into viral replication inhibition, drug synergism, pharmacokinetic studies, and modeling of CYP-mediated interactions including boosting effect dynamics.

Side Effects (For Reference Only in Research Models)

Modeling data from clinical analogs suggest potential effects including diarrhea, nausea, fatigue, headache, muscle pain, elevated lipid profiles, liver enzyme changes, and drug interaction outcomes. Severe effects may include pancreatitis, hyperglycemia, and hepatotoxicity. These data inform safety planning and dose-limit strategies in experimental designs.

Disclaimer

Aluvia Lopinavir Ritonavir Tablets are strictly intended for laboratory research use only. Not for human or veterinary therapeutic or diagnostic use.